Incidence of endocrine toxicities in patients with solid tumor malignancies receiving curative-intent immune checkpoint inhibitor (ICI) therapy: A single institution experience
Journal of Oncology Pharmacy Practice
Published online on February 26, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionImmune checkpoint inhibitors (ICIs) are used across many solid tumor malignancies. The mechanism varies depending on the agent but ultimately leads to immune system activation by targeting key regulators of immune tolerance. Toxicities occur ...
IntroductionImmune checkpoint inhibitors (ICIs) are used across many solid tumor malignancies. The mechanism varies depending on the agent but ultimately leads to immune system activation by targeting key regulators of immune tolerance. Toxicities occur ...